medRxiv preprint doi: https://doi.org/10.1101/2021.03.13.21253527; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

PD-1^{high}CXCR5⁻CD4⁺ Peripheral Helper T (Tph) cells Promote 1 Tissue-Homing Plasmablasts in COVID-19 2 3 Hiromitsu Asashima^{1, 2}, Subhasis Mohanty³, Michela Comi^{1, 2}, William E. Ruff^{1, 2}, Kenneth B. 4 Hoehn⁴, Patrick Wong², Inessa Cohen^{1, 2}, Sarah Coffey^{1, 2}, Khadir Raddassi^{1, 2}, Omkar 5 Chaudhary³, Avraham Unterman⁵, Brinda Emu³, Steven H. Kleinstein^{2, 4, 6}, Ruth R. Montgomery⁷, 6 7 Akiko Iwasaki^{2, 3, 8}, Charles S. Dela Cruz⁵, Naftali Kaminski⁵, Albert C. Shaw³, David A. Hafler^{1, 2,} #. Tomokazu S. Sumida^{1, 2, #} 8 9 Affiliations 10 1. Department of Neurology, Yale School of Medicine, New Haven, CT, USA 11 12 2. Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA 13 3. Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, 14 Yale University, New Haven, CT, USA. 4. Department of Pathology, Yale School of Medicine, New Haven, CT, USA. 15 16 5. Section of Pulmonary, Critical Care and Sleep Medicine Section, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA. 17 18 6. Inter-Departmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA 19 20 7. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 21 8. Howard Hughes Medical Institute, Chevy Chase, MD, USA. 22 *Corresponding author: 23 Tomokazu Sumida (tomokazu.sumida@yale.edu) 24 Dr. or Dr. David Hafler (david.hafler@yale.edu) Departments of Neurology and Immunobiology, Yale School of 25 Medicine, New Haven, CT, USA 26 Phone: 203-747-4802 27

28

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Summary

A dysregulated immune response against coronavirus-2 (SARS-CoV-2) plays a critical role in 30 the outcome of patients with coronavirus disease 2019 (COVID-19). A significant increase in 31 circulating plasmablasts is characteristic of COVID-19 though the underlying mechanisms and 32 its prognostic implications are not known. Here, we demonstrate that in the acute phase of 33 COVID-19, activated PD-1^{high}CXCR5⁻CD4⁺ T cells, peripheral helper T cells, (Tph) are 34 significantly increased and promote inflammatory tissue-homing plasmablasts in patients with 35 stable but not severe COVID-19. Analysis of scRNA-seq data revealed that plasmablasts in 36 stable patients express higher levels of tissue-homing receptors including CXCR3. The 37 increased Tph cells exhibited "B cell help" signatures similar to that of circulating T follicular 38 helper (cTfh) cells and promoted B cell differentiation *in vitro*. Compared with cTfh cells, Tph 39 40 cells produced more IFN γ , inducing tissue-homing chemokine receptors on plasmablasts. 41 Finally, expansion of activated Tph cells was correlated with the frequency of CXCR3⁺ 42 plasmablasts in the acute phase of patients with stable disease. Our results demonstrate a novel role for Tph cells in acute viral immunity by inducing ectopic, antibody secreting 43 44 plasmablasts.

- 45
- 46

47 Key words: PD-1^{high}CXCR5⁻CD4+ peripheral helper T (Tph) cells, tissue-homing
48 plasmablasts, IFNγ, COVID-19

49 Introduction

SARS-CoV-2 causes a wide spectrum of symptoms ranging from asymptomatic infections 50 51 to acute respiratory distress syndrome (ARDS)^{1,2}. COVID-19 is the clinical manifestation of SARS-CoV-2 infection and it has become clear that a dysregulated immune response against 52 SARS-CoV-2 is central in determining disease severity. Increased frequencies of circulating 53 neutrophils with low frequencies of natural killer cells or CD4⁺ T cells are characteristic of 54 peripheral blood immune profiles observed in patients with COVID-19^{3–6}. The generation of a 55 robust antibody response is critical for clearing the virus and alterations in B cell lineages with 56 57 the expansion of plasmablasts are reported both in the blood and bronchoalveolar lavage of patients with COVID-19⁶⁻⁸. The increase in plasmablasts, which can represent up to 30% of 58 circulating B cells, is observed in a subset of patients comparable to acute Ebola or dengue 59 virus infections^{9,10}. 60

During the acute phase of COVID-19, activated B cells differentiate into plasmablasts that 61 migrate to target inflammatory tissues, especially the lungs¹¹, indicating that trafficking patterns 62 of plasmablasts are important in the disease course. These plasmablasts express tissue-63 specific chemokines together with adhesion molecules and produce organ-specific protective 64 antibodies for viral control^{12,13}. This rapid antibody response is critical as the early containment 65 of virus reduces the risk of cytokine storm syndrome with excessive accumulation of immune 66 cells in the lung parenchyma with ARDS. Despite this important role, the control of expansion 67 and migration capacity of plasmablasts in patients with COVID-19 remains poorly understood. 68

During the adaptive immune response, T follicular helper (Tfh) cells play crucial roles 69 in B cell differentiation^{14,15}. Circulating CXCR5⁺CD4⁺ T cells, termed cTfh cells, support B cell 70 71 differentiation in blood while Tfh cells located in lymphoid tissues allow B cell differentiation in lymph nodes¹⁶. Intriguingly, while the plasmablast response correlates with the cTfh responses 72 in subjects recovered from COVID-19¹⁷, there is no correlation between the frequency of cTfh 73 74 cells and that of plasmablasts in symptomatic patients with COVID-19⁶. Moreover, in the acute 75 phase of SARS-CoV-2 infection, a striking absence of germinal centers in lymphoid organs 76 was reported, similar to SARS, but activation-induced cytidine deaminase (AID)-expressing B 77 cells are still preserved¹⁸. These data suggest that activated helper T cells other than Tfh cells support the differentiation of B cells at extra-follicular regions in acute phase of COVID-19. 78

To examine the mechanism of T cell regulation of plasmablast differentiation in COVID-19, we investigated the characteristics of B and T cells in patients by single cell RNA-seq (scRNA-seq) and flow cytometry datasets. Here, we report that PD-1^{high}CXCR5⁻CD4⁺ T cells,

so called peripheral helper T (Tph) cells^{19,20}, are significantly increased and positively 82 correlated with the frequency of plasmablasts in peripheral blood in patients with COVID-19. 83 These Tph cells exhibit "B cell help" signatures to a similar degree as cTfh cells, but also 84 85 express more inflammatory chemokine receptors including CCR2 and CCR5. In vitro experiments indicate that PD-1^{high}CXCR5⁻ Tph cells have higher IFN_γ production, which 86 promotes CXCR3 expression and differentiation of plasmablasts. Finally, we demonstrate that 87 CXCR3⁺ tissue-homing plasmablasts are significantly increased in patients with stable 88 COVID-19 while they are decreased in patients with severe disease. These findings provide 89 90 a mechanism for the increase of plasmablasts apart from Tfh cells in the acute phase of COVID-19. Thus, the induction of plasmablast trafficking to inflammatory sites by activated 91 92 PD-1^{high}CXCR5⁻ Tph cells is important for disease control in the acute phase of COVID-19.

93

94 **Results**

95 Expanded plasmablasts express higher tissue-homing molecules in patients with 96 stable COVID-19

We first confirmed that the frequency of plasmablasts is significantly increased in the 97 peripheral blood in patients with COVID-19 by flow cytometry^{3,21} (Figure 1a, Supplemental 98 Table 1, 2). To further understand the characteristics of B cells in patients with COVID-19, we 99 next analyzed previously collected scRNA-seq data⁵ and sub-clustered B cells (total 13550 100 cells from 31 samples) into eight clusters according to gene expression (Figure 1b, 1c, 101 102 Supplemental Figure 1a, 1b, Supplemental Table 3). We identified naïve B cells 103 (*MS4A1*⁺*IGHD*⁺), germinal center-like B cells (*MS4A1*⁺*NEIL1*⁺; GC-like B cells), intermediate memory B cells (IGHD⁺CD27⁺), memory B cells (MS4A1⁺CD27⁺), and two plasma cells 104 105 clusters: plasmablasts ($MZB1^+CD38^+$) and Ki67⁺ plasmablasts ($MZB1^+CD38^+MKI67^+$), in accordance with a previous report²² (plasmablasts; 912 cells and Ki67⁺ plasmablasts; 537 106 cells). GC-like B cells also express CD9^{23,24} (Supplemental Figure 1b). Additionally, we were 107 able to identify two additional clusters, namely, FCRL5⁺ B cells (MS4A1⁺FCRL5⁺) and CD1c⁺ 108 109 B cells (*MS4A1*⁺*CD1C*⁺). FCRL5⁺ B cells also express higher levels of *ITGAX* and *ZEB2* than the other B cells, and this cluster was similar with atypical B cells or double-negative (DN) 110 cells^{25–27} (Supplemental Figure 1b). CD1c⁺ B cells express higher levels of CD52 compared 111 to the other B cell subclusters, which implies that gene expression signatures of this cluster 112 resemble marginal zone-like B cells^{28,29}. There was no significant difference in the clonal 113

114 diversity or the frequency of unmutated clones between the two clusters of plasmablasts (Supplemental Figure 1c, 1d). Both plasmablast clusters expressed IgG, which indicated that 115 they had undergone class-switching (Figure 1d). Ki67⁺ plasmablasts had a significantly lower 116 frequency of somatic hypermutations (SHM) in COVID-19 subjects compared with the other 117 plasmablasts (Figure 1e). The proportion of GC-like B cells was significantly decreased and 118 FCRL5⁺ B cells were increased in patients with progressive COVID-19. These observations 119 imply that the extrafollicular response is related to B cell activation in patients with COVID-120 19³⁰ (Supplemental Figure 1e). To further examine the characteristics of each single cell RNA 121 cluster, we determined gene expression levels as related to B cell function³¹ (Supplemental 122 Figure 1f). It was of interest that the expression level of CXCR3, the receptor necessary for 123 trafficking to sites of inflammation, was upregulated in plasmablast clusters, especially in Ki67⁺ 124 plasmablasts. Homing receptors³², which promote homing to lymph nodes (CCR7, SELL), 125 were highly expressed in healthy control plasmablasts, while Ki67⁺ plasmablasts in stable 126 127 COVID-19 patients expressed tissue-homing molecules (CXCR3, CCR2) (Figure 1f, 1g). Taken together, Ki67⁺ plasmablasts trafficking to inflammatory sites are a unique population 128 129 expanded in stable patients in contrast to patients with severe COVID-19, and these acute plasmablast responses might be beneficial for hosts to prevent viral expansion at inflammatory 130 131 tissues.

132

PD-1^{high}CXCR5⁻ Tph cells are significantly increased in patients with COVID-19 and have a unique gene expression profile

Tfh cells provide essential B cell help during the adaptive immune response, and 135 circulating Tfh (cTfh) cells share functional properties with Tfh cells¹⁶. Notably, PD-136 1^{high}CXCR5⁻ Tph cells, that are reported to be associated with extra follicular B cell 137 differentiation²⁰, were significantly increased in the blood of COVID-19 patients, in addition to 138 significant increase in PD1^{high/int}CXCR5⁺ Tfh cells (Figure 2a, Supplemental Figure 2a, 2b). 139 Tph cells were barely detected in healthy blood and moreover, correlated in COVID-19 140 patients with the frequency of circulating plasmablasts (Figure 2b, Supplemental Figure 2c) 141 but not with clinical characteristics (age, body mass index (BMI), and sex) (Supplemental 142 Figure 3a-c). The increase of PD-1^{high}CXCR5⁻ Tph cells and the positive correlation between 143 these cells and plasmablasts in the acute phase of COVID-19 patients were validated from 144 another dataset⁶ (Supplemental Figure 4a-c). 145

146 To further characterize these T helper populations, six subsets of memory CD4⁺ T cells (CD45RA⁻CD4⁺T cells), categorized by PD-1 and CXCR5 expression levels, were sorted and 147 gene expression profiles were examined by bulk RNA-seq (Figure 2c). Principal component 148 analysis (PCA) placed PD-1^{high}CXCR5⁻ Tph cells at a distinctive position relative to other 149 subsets, indicating a unique gene expression profile. PD-1^{high}CXCR5⁻ Tph cells had similar 150 expression of Tfh-related genes¹⁹ compared to PD-1^{high}CXCR5⁺ Tfh cells and expressed 151 molecules including MAF, TIGIT, SLAMF6, and IL21, which are important for Tfh functions 152 (Figure 2d). PD-1^{int}CXCR5⁺ Tfh cells also expressed these genes, but had less ICOS 153 expression than PD-1^{high}CXCR5⁺ Tfh cell, suggesting that PD-1^{high}CXCR5⁺ Tfh cells are more 154 activated cTfh cells¹⁴. We identified 100 genes that were differentially expressed in PD-155 1^{high}CXCR5⁻ Tph cells compared with PD-1^{high}CXCR5⁺ Tfh cells (|Log2FC| >1, FDR <0.05) 156 (Figure 2e); PD-1^{high}CXCR5⁻ Tph cells showed marked upregulation of tissue-resident 157 chemokine receptors, including CCR2, CCR5 and CX3CR1 (Figure 2f, Supplemental Figure 158 159 3d). Additionally, we surveyed the expression of T cell lineage genes, and found that Th1-like signatures (CXCR3, TBX21, STAT1) were highly expressed in PD-1^{high}CXCR5⁻ Tph cells 160 161 (Supplemental Figure 3e). Thus, PD-1^{high}CXCR5⁻ Tph cells exhibit "B cell help" signatures to a similar degree as cTfh cells, but with a unique gene expression profile. 162

163

PD-1^{high}CXCR5⁻ Tph cells promote B cell differentiation, and produce more IFN_γ than PD-1^{high}CXCR5⁺ Tfh cells

We examined whether PD-1^{high}CXCR5⁻ Tph cells promote B cell differentiation in 166 vitro. As with PD-1^{high}CXCR5⁺ Tfh cells, these cells induce memory B cells into plasmablasts, 167 and initiated IgG production (Figure 3a, 3b). Stimulation with anti-CD3/CD28 antibodies 168 induced greater IFN_γ and IL-10 production from PD-1^{high}CXCR5⁻ Tph cells (Figure 3c), which 169 is of interest as IFN_{γ} is known to upregulate CXCR3 expression during B cell differentiation³³. 170 171 We observed that CXCR3 expression on plasmablasts was upregulated in a dose dependent manner by IFN_y while IL-10 was not (Figure 3d, 3e). Moreover, besides CXCR3, other 172 173 inflammatory tissue-homing receptors such as CCR2 were upregulated, but CXCR4 was not (Figure 3f). These data indicate that PD-1^{high}CXCR5⁻ Tph cells promote B cell differentiation 174 and have a capacity to induce plasmablasts which express homing-molecules for 175 176 inflammatory tissues via IFNy production.

- 6 -

177 The proportion of activated PD-1^{high}CXCR5⁻ Tph cells are significantly increased in

stable as compared to severely ill patients with COVID-19 and are positively 178

correlated with CXCR3⁺ plasmablasts 179

To investigate the characteristics of PD-1^{high}CXCR5⁻ Tph cells *in vivo*, we evaluated the 180 specific gene signatures of this subset (Supplemental Table 4). Compared to the other five 181 subsets in memory CD4⁺ T cells, CXCR6, LAG3, and PRR5L were significantly upregulated, 182 while CHD7, ZBTB20, ZNF251, GRK25, and GPRASP1 were significantly downregulated in 183 PD-1^{high}CXCR5⁻ Tph cells (Figure 4a, 4b). Flow cytometry analysis also showed the same 184 trend of upregulation of LAG3 and CXCR6 expressions (Supplemental Figure 5a, 5b). 185 Embedding these gene lists with CD4⁺ T cell clusters from our scRNA-seg data set⁵, we found 186 that dividing CD4⁺ T cells best fit with these signatures (Figure 4c). We previously reported 187 188 that dividing CD4⁺ T cells share the characteristics of HLA-DR⁺CD38⁺ activated T cells⁵, and indeed, more than half of the activated CD4⁺ T cells were in the PD-1^{high}CXCR5⁻ Tph cell 189 population (Figure 4d). In contrast, 15% of PD-1^{high}CXCR5⁻ Tph cells exhibited an activated 190 state among all COVID-19 samples (data not shown), with a significantly higher proportion in 191 192 patients with stable disease as compared to patients with progressive disease (Figure 4e). We confirmed that these observations were not highly confounded by known risk factors for 193 194 disease severity, such as age, BMI, and sex (Supplemental Figure 5c-e).

Finally, we observed a positive correlation between activated PD-1^{high}CXCR5⁻ Tph cells 195 and CXCR3⁺ plasmablasts (Figure 4f). There was no difference in the proportion of PD-196 1^{high}CXCR5⁻ Tph cells between stable and progressive patients at baseline, but interestingly 197 they increased in progressive patient over time and reached significance at two weeks after 198 the baseline (Supplemental Figure 5f, Supplemental Table 5). In contrast, the significantly 199 elevated frequency of activated PD-1^{high}CXCR5⁻ Tph cells in stable patients at baseline 200 became less significant over time (Supplemental Figure 5q). These data demonstrate that 201 202 prompt increased HLA-DR⁺CD38⁺ activated PD-1^{high}CXCR5⁻ Tph cells are one of the early responses in stable patients, which is also positively correlated with tissue-homing CXCR3⁺ 203 204 plasmablasts.

205

206 Discussion

Here, we performed a bidirectional-analyses between T cells and B cells in patients with 207 COVID-19 by both bulk and scRNA-seq studies with B-cell receptor (BCR) repertoire analysis 208 and *in vitro* assays. PD-1^{high}CXCR5⁻ Tph cells were increased among the PBMCs of patients 209 with COVID-19 and were positively correlated with the frequency of plasmablasts. These PD-210 1^{high}CXCR5⁻ Tph cells had a similar gene profile with cTfh cells focused on "B cell help" 211 signatures and promoted B cell differentiation in vitro. Moreover, CXCR3⁺ tissue-homing 212 plasmablasts were markedly increased in patients with stable but not severely ill patients with 213 COVID-19 where we hypothesize that activated PD-1^{high}CXCR5⁻ Tph cells promoted these 214 plasmablasts via IFNy production. Thus, these data suggest that tissue homing plasmablasts 215 are important for the clinical outcome of patients with COVID-19 (Supplemental Figure 6). 216

PD-1^{high}CXCR5⁻Tph cells were first described in the synovial fluid of rheumatoid arthritis 217 and the peripheral blood of patients with systemic lupus erythematosus (SLE)^{19,34}, indicating 218 an important role in autoimmune diseases with tissue specific, ectopic antibody production. 219 220 Our data extend those findings, demonstrating a role for these Tph cells in acute viral infections. We show that not only PD-1^{high/int}CXCR5⁺ cTfh cells, but also PD-1^{high}CXCR5⁻ Tph 221 222 cells are significantly increased in peripheral blood of COVID-19 patients supporting the expansion of plasmablasts. One of the common signals between the acute phase of COVID-223 19 and chronic autoimmune conditions such as SLE are type-1 interferon (IFN) 224 signatures^{5,35,36}. Type-1 IFN (IFN-I) is reported to downregulate CXCR5 expression on human 225 T cells³⁷ and our recent data showed that IFN-I upregulates PD-1 expression and 226 downregulates CXCR5 expression in an *in vitro* assay³⁸. Intriguingly, most of the genes unique 227 to PD-1^{high}CXCR5⁻ Tph cells such as CXCR6, LAG3, ZBTB20, and CHD7 had the same 228 directions for their expression levels after type-1 IFN stimulation³⁸. These data indicate that 229 230 type-1 IFN might be one of the key signals to induce these Tph cells.

Patients with COVID-19 have a striking loss of GCs in lymph nodes with underlying extrafollicular B cell responses, particularly in severe cases^{18,39}. Our scRNA-seq data showed an increase in FCRL5⁺ B cells in progressive patients (Supplemental Figure 1e), which supports this observation. Our results highlight the characteristics of PD-1^{high}CXCR5⁻ Tph cells as: 1) lacking CXCR5 expression, important for the entry in GCs; 2) producing more IFN γ that is similar to T cells residing in the extra-follicular regions of lymph nodes¹⁸; and 3) exhibiting

- 8 -

237 highly overlapping signatures with dividing CD4⁺ T cells that are positively correlated with the proportion of Ki67⁺ plasmablasts⁴⁰, which had lower SHM frequencies in our scRNA-seq data. 238 These findings suggest that circulating PD-1^{high}CXCR5⁻ Tph cells may be the counterpart of T 239 cells which promote more extra-follicular responses²⁰. On the other hand, we could detect 240 these T cells in peripheral blood of stable COVID-19 patients despite the lack of extrafollicular 241 signatures in such patients. In acute viral infections, extra-follicular responses are thought to 242 bridge between innate- and GC-responses of B cells⁴¹. Many effector molecules control the 243 switch between GC- and extra-follicular responses⁴², which is dynamically changed in the 244 acute phase of COVID-19. Though it might be difficult to conclude the direct relationship 245 between extra-follicular responses and blood PD-1^{high}CXCR5⁻ Tph cells from our dataset, the 246 longitudinal assessment of these T cells together with their spatial analysis with B cells in 247 248 lymph nodes will clarify these relationships.

249 In the Salmonella infected mouse model, the antibody responses important for the bacteria clearance are established by day 3 through 5 weeks, and GC formation is observed 250 251 approximately one month after infection, indicating GC formation is not necessary for these early responses⁴³. Similarly, in COVID-19 human samples, earlier antibody responses are 252 253 likely to be associated with better recovery^{44,45}, which is consistent with our findings that the 254 rapid induction of inflammatory tissue-homing plasmablasts was linked with a better clinical outcome. Additionally, we detected that PD-1^{high}CXCR5⁻ Tph cells in the activated state had 255 the capacity to support the induction of tissue-homing plasmablasts, and these T cells were 256 significantly increased in stable patients at the earlier stage of disease. The significant 257 difference in the frequency of activated PD-1^{high}CXCR5⁻ Tph cells between stable and 258 progressive patients disappears over time, indicating that the prompt induction of activated 259 PD-1^{high}CXCR5⁻ Tph cells might be critical for the promotion of tissue homing plasmablasts to 260 effectively remove virus from inflamed tissues and thus linked with better clinical outcomes. 261 Not only sex differences³, but also genetic backgrounds are reported to be related to T cell 262 activation^{46,47} and further analyses combined with these factors will lead to the more precise 263 264 identification of patients at higher risk, and thus expected to be valuable for the development 265 of personalized treatments.

Finally, our investigations have implications for understanding T-B cell interaction in human viral infections and provide a potential framework for assessing immune response to

SARS-CoV-2 and other IFN-I inducing viral infections. In summary, our data implicate PD-268

- 1^{high}CXCR5⁻ Tph cells as triggering acute protective plasmablast responses with direct 269
- relevance in COVID-19 pathophysiology. Moreover, these data shed light on how T cells can 270
- affect B cell differentiation in COVID-19 and provide potential insights into the role of PD-271
- 1^{high}CXCR5⁻ Tph cells on a variety of immune-mediated diseases with possible contribution of 272
- aberrant T-B interaction, including chronic autoimmune diseases. 273
- 274

275 Methods

276 Ethics Statement

This study was approved by the Institutional Review Board at the Yale School of Medicine (2000027291REG and FWA00002571, Protocol ID. 2000027690). Informed consent was obtained from all enrolled patients, healthcare workers and healthy donors.

280

281 Patients and Samples

Adult patients (≥18 years old) admitted to Yale-New Haven Hospital, positive for SARS-CoV-2by RT-PCR from nasopharyngeal and/or oropharyngeal swabs, and able to provide informed consent (surrogate consent accepted) were eligible (Supplemental Table 1). Individuals with active chemotherapy against cancers, pregnant patients, patients with background hematological abnormalities, patients with autoimmune diseases and patients with a history of organ transplantation and on immunosuppressive agents, were excluded from this study.

For the characterization of T cells and B cells, the flow data deposited in the Yale IMPACT 288 Biorepository study were analyzed as described elsewhere^{3,21}. All the patients were admitted 289 290 between 30 March and 27 May 2020 and hospitalized. Only the baseline data were analyzed except for the analysis of time kinetics (Supplemental Table 2). All the experiments were 291 292 performed on fresh peripheral blood mononuclear cells (PBMCs), and samples were drawn on the average of 11.8 days after first symptoms. 92 patients with COVID-19 and 64 COVID-293 294 19-uninfected healthcare workers (HCs) were enrolled. COVID-19 patients who required admission to the ICU had been classified as "progressive" and 27.8% of them were expired. 295 The other patients classified as "stable" were all discharged without ICU admission. For the 296 patients who are 90 years-old or older, their ages were protected health information, and '90' 297 was put as the surrogate value for the analyses. HCs were all negative in both PCR and 298 299 serology tests.

Single cell RNA-seq (scRNA-seq) was performed on cryopreserved PBMC samples of 10 patients with COVID-19 following the same criteria as above and 13 age- and sex- matched controls. All the samples were drawn on the average of 11.7 days after first symptoms. Control samples were already collected before the first report of COVID-19 in 2018. From eight of ten patients with COVID-19, PBMC samples from two different time points had been analyzed. Four patients had been classified as "progressive", who required admission to the ICU, and

the other six patients classified as "stable" who were hospitalized and all discharged, and the same criteria as flow data. We have described the full cohort elsewhere⁵.

All the other experiments which include *in vitro* experiments and bulk RNA-seq were performed with fresh PBMCs at the baseline. All the patients were admitted between 21st July and 22nd Jan 2021.

311

312 Peripheral blood mononuclear cells isolation

PBMCs were prepared from whole blood by Ficoll gradient centrifugation (Histopaque (Sigma)
in the Yale IMPACT Biorepository study and Lymphoprep (Stemcell) in other experiments).
The PBMC layer was collected into a new 50-ml tube and washed twice with PBS to remove
any remaining Lymphoprep/Histopaque. As for scRNA-seq and flow cytometry, the pelleted
cells were treated with ACK buffer for red cell lysis. All the other experiments including bulk
RNA-seq samples were processed without lysis buffer.

319

320 Flow Cytometry and sorting

In the Yale IMPACT Biorepository study, the staining was performed mainly in two separate 321 panels for (1) T cell surface staining and (2) B cell surface staining. PBMCs were plated at 1-322 2×10^6 cells in a 96-well U-bottom plate, and resuspended in Live/Dead Fixable Aqua 323 (ThermoFisher) for 20 min at 4 °C. Following a wash, cells were then blocked with Human 324 TruStan FcX (BioLegend) for 10 min at room temperature. Cocktails of desired staining 325 antibodies were directly added to this mixture for 30 min at room temperature. Before analysis, 326 cells were washed and resuspended in 100 µl of 4% paraformaldehyde for 30 min at 4 °C. We 327 have described the detailed methods elsewhere³. The adopted antibodies and their clones 328 were as follows. Anti-CD3 (UCHT1), anti-CD19 (SJ25C1), anti-CD4 (SK3), anti-CD45RA 329 (HI100), anti-PD-1 (EH12.2H7), anti-CD38 (HIT2), anti-CXCR5 (RF8B2), anti-CXCR3 330 (1C6/CXCR3), anti-CD20 (2H7), anti-CD27 (M-T271), anti-IgD (IA6-2). 331

For other experiments, freshly isolated PBMCs were stained with cocktails of desired staining antibodies for 30 minutes at 4°C. Specific T cell and B cell subsets were sorted on a Sony MA900 cell sorter. The adopted antibodies and their clones were as follows. Anti-CD4 (OKT4), anti-CD19 (HIB19), anti-CD20 (2H7), anti-CD27 (M-T271), anti-CD38 (HIT2), anti-CD138 (MI15), anti-PD-1 (EH12.2H7), anti-LAG3 (11C3C65), anti-CCR2 (K036C2), ant-CCR5

(J418F1), anti-CXCR3 (G025H7), anti-CXCR6 (K041E5), anti-CX3CR1 (2A9-1) (all from
Biolegend); anti-CD3 (UCHT1), anti-CD45RA (HI100), anti-CXCR5 (RF8B2) (all from BD
Biosciences).

340

341 T-B-cell co-culture experiments

Co-culture experiments were performed referenced as described previously¹⁹. In brief, sorted 342 343 T cell populations (5000-10000 cells) from PBMCs of patients with COVID-19 were co-cultured with autologous CD20+CD27+ memory B cells at a ratio of 1:3 in 200 µl of RPMI 1640 medium 344 (Gibco) supplemented with 10% fetal bovine serum (FBS), 2 nM L-glutamine, and 100 U/ml 345 penicillin, 100 μ g/ml streptomycin (Lonza), stimulated with SEB (1 μ g/ml) and LPS (1 μ g/ml) 346 for 7 days. Supernatants were collected, and total IgG (Invitrogen) was measured by ELISA. 347 Cells were harvested and analyzed by flow cytometry, with plasma cells defined as 348 CD27^{high}CD138⁺ cells. 349

350

351 B cell differentiation in vitro

We extracted PBMCs from healthy volunteers. After the isolation of CD19+ B cells from PBMCs using Human B cell isolation kit (Stemcell Technologies), CD20+CD27+ memory B cells were sorted on a FACS Aria (BD Biosciences) and stimulated with CD40L (0.05 μ g/ml) (Enzo), IL-21 (20 ng/ml) (R&D systems) and other cytokines (all from R&D systems) in culture medium the same as above. After 7 days, CD27^{high}CD138+ plasma cells were sorted for gene expression analysis by qPCR.

358

359 T cell stimulation in vitro

We extracted PBMCs from patients with COVID-19. Each subset of memory CD4+ T cells based on the expression levels of PD-1 and CXCR5 were stimulated with anti-CD3/CD28 (each 1 μg/ml; BD Biosciences) for 48 hrs and cytokine levels were measured by ELISA (all from R&D systems) according to the manufacturer's instructions. 1% Triton X-100 for 60 minutes at room temperature was added before ELISA to reduce risk from any potential virus in the supernatant⁴⁸.

366

367 Quantitative PCR

Total RNA was extracted using RNeasy Micro Kit (QIAGEN) according to the manufacturer's instructions. cDNA was synthesized with SuperScript IV VILO Master Mix (Invitrogen). cDNAs were amplified with Taqman probes (Taqman Gene Expression Arrays) and TaqMan Fast Advanced Master Mix on a StepOne Real-Time PCR System (Applied Biosystems) according to the manufacturer's instructions. The RNA expression was measured relative to *B2M* expression. The adopted Taqman probes were as follows. *CXCR3* (Hs01847760_s1), *CXCR4* (Hs00607978_s1), *CCR2* (Hs00356601_m1).

375

376 Single cell RNA-seq data processing

A PBMC scRNA-seq data set which had been previously performed and reported by us⁵ was 377 reanalyzed. In brief, single cell barcoding of PBMC and library construction had been 378 performed using the 10x Chromium NextGEM 5 prime kit according to manufacturer's 379 instructions. Libraries had been sequenced on an Illumina Novaseg 6000 platform. Raw reads 380 had been demultiplexed and processed using Cell Ranger (v3.1) mapping to the GRCh38 381 (Ensembl 93) reference genome. Resulting gene-cell matrices had been analyzed using the 382 383 package Seurat^{49,50} in the software R (v3.6.2) including integration of data, clustering, multiplet identification and cell type annotation. We have described the detailed methods elsewhere⁵. 384 385 The annotated R object was used for sub-clustering of B cells.

The three cell populations, "Memory B cells", "Naïve B cells " and "Plasma cells" in 386 total PBMCs were re-clustered to obtain a finer cell type granularity. To remove batch- and 387 single-donor effects, we integrated all 31 samples of these populations into one dataset using 388 reference-based anchor finding and integration workflow. We chose 2 healthy donor samples 389 (C27 and C32) and 2 COVID-19 samples (NS1B and TS3A), which have enough B cell 390 numbers, as references for anchor finding and integration. The top 2000 variable genes were 391 selected, and integration anchors were determined by "FindIntegrationAnchors" without k.filter 392 for low cell numbers in some samples. These anchors were used to integrate the data using 393 the "IntegrateData" function with top 30 dimensions and scaled. The top 17 PCs were used 394 for data integration and downstream steps, along with a clustering resolution of 0.4. Cluster-395

396 specific gene expression profiles were established using the "FindAllMarkers" per cluster and 397 per subset to annotate the clusters. Doublet clusters were determined by co-expression of 398 heterogeneous lineage markers (e.g., *MS4A1* and *CD3*). These clusters were removed prior 399 to finalizing the UMAPs.

400

401 **B cell receptor repertoire analysis**

B cell receptor (BCR) V(D)J repertoire data processing, clonal clustering, and unmutated 402 germline ancestor sequence reconstruction was previously performed in⁵. Briefly, V(D)J 403 denes aligned to the IMGT/GENE-DB v3.1.26⁵¹ germline reference database using IgBLAST 404 v.1.15.0⁵². Cells with multiple IGH V(D)J sequences were assigned to the most abundant 405 IGH V(D)J sequence by UMI count, and ties were broken by the first identified heavy chain. 406 407 Non-functional sequences were removed. V(D)J sequences within each patient were 408 grouped into clonal clusters by first partitioning based on common IGHV gene annotations, 409 IGHJ gene annotations, and junction lengths. Within these groups, sequences differing from one another by a length normalized Hamming distance of 0.15 within the junction region 410 411 were defined as clones by single-linkage clustering using Change-O v.1.0.0⁵³. Germline sequences were reconstructed for each clone with the D segment and N/P regions masked 412 413 (replaced with "N" nucleotides) using the CreateGermlines.py function within Change-O v.1.0.0. 414

Somatic hypermutation frequency was calculated using SHazaM v1.0.2.999⁵⁴ as the 415 frequency of non-ambiguous nucleotide differences along the IGHV gene segment (IMGT 416 positions 1-312) between each sequence and its inferred germline ancestor. To identify 417 unmutated B cell clones of different cell types and isotypes. B cell clones were separated by 418 cell type and isotype and considered "unmutated" if the median somatic hypermutation 419 frequency of their constituent sequences was < 1%. This cutoff was also used in^{5,55}. To 420 quantify B cell clonal diversity, we calculated Simpson's diversity within each patient for 421 422 plasmablast subsets using the alphaDiversity function of Alakazam v1.0.2.999⁵³. To account for differences in sequence depth, the number of sequences within each patient were down-423 sampled to the same number of sequences, and the mean of 100 such re-sampling 424 repetitions was reported. Only patients with at least 30 B cells were included in diversity 425 426 calculations. All statistical analyses of BCR sequences were performed with R (v3.6.1). 427

- 15 -

428

429 Bulk RNA-seq

- 430 cDNA and library preparation and sequencing:
- 431 RNAs were isolated using RNeasy Plus Micro Kit (QIAGEN) and cDNAs were generated
- 432 using the SMART-Seq v4 Ultra Low Input RNA Kit for sequencing (Takara/Clontech).
- 433 Barcoded libraries were generated by the Nextera XT DNA Library Preparation kit (Illumina)
- and sequenced with a 2x100 bp paired-end protocol on the HiSeq 4000 Sequencing System
- 435 (Illumina).
- 436

437 Bulk RNA-seq data analysis:

- Low quality ends (less than phred score=30) and short read length (minimum length=30)
- 439 was trimmed using PRINSEQ++⁵⁶ (version1.2). Trimmed reads were aligned to the hg38
- 440 genome reference using STAR⁵⁷ (v2.7.1), and subsequently RSEM (RNA-Seq by
- 441 Expectation-Maximization)⁵⁸ was used to count reads mapping to the genes from Ensembl
- release 93. Top 1000 genes by variance were analyzed for PCA. Heat maps show row-
- 443 normalized relative gene expression z-scores across columns. Pairwise differential
- 444 expression was performed using the R package DESeq2⁵⁹. The cutoff value to select
- differentially expressed genes is provided in each figure legend.
- 446 These data will be publicly available prior to publication .
- 447

448 Statistical analysis

- All statistical analyses were performed using R or GraphPad Prism 7 (GraphPad Software).
- 450 Detailed information about statistical analysis, including tests and values used, is provided
- 451 in the figure legends.
- 452

453 Figure Legends

454

455 Figure 1

The divergent immunological features of B cells in stable and progressive COVID-19 patients.

Plasmablasts of patients with stable COVID-19 express inflammatory tissue-homing 458 receptors. a, Representative flow data of CD19⁺CD27⁺CD38⁺ plasmablasts (left). The 459 proportion of plasmablasts between healthcare workers (HCs) (n=15) and both stable and 460 progressive COVID-19 patients (COVID) (n=51) were evaluated by two-tailed unpaired 461 Student's t-test were evaluated (right). b, UMAP representation of sub-clustered B cells from 462 HCs (n = 13) and COVID-19 samples (n = 18 from 10 patients). Eight subclusters were 463 464 identified. c, Canonical cell markers for cluster delineation. Data are colored according to expression levels. d, Fractional abundance of IGHA (dark green), IGHD (orange), IGHG (pink), 465 466 and IGHM (light green) cells in each cluster. PBs denote plasmablasts. e, Frequency of somatic hypermutation (SHM) in each cluster. Each dot denotes a patient (combined early and 467 468 late samples, n=10). A Wilcoxon test was evaluated, and p value is reported above plasmablast clusters. PBs denote plasmablasts. f, Heatmap of tissue-homing receptors³² 469 470 among HC, stable COVID-19 (stable), and progressive COVID-19 (progressive) in clusters of both plasmablasts and Ki67+ plasmablasts. Average expression per subject for each gene is 471 472 shown. **q**, Representative flow data of CXCR3 expression on CD19⁺CD27⁺CD38+ plasmablasts in COVID-19 patients (left). The proportions of CXCR3⁺ plasmablasts between 473 stable (n= 31) and progressive (n=20) COVID-19 patients were evaluated by two-tailed 474 unpaired Student's t-test (right). 475

476

477 **Figure 2**

478 The characteristics of PD-1^{high}CXCR5⁻ Tph cells

PD-1^{high}CXCR5⁻ Tph cells have characteristic gene expressions and are increased in COVID 19 patients. **a**, Representative flow data of PD-1^{high}CXCR5⁻ Tph cells in each group (left), the
 proportion of these T cells among healthcare workers (HC) (n=55), stable COVID-19 patients
 (Stable) (n=56), and progressive patients (Progressive) (n=36). One-way ANOVA with Dunn's
 multiple comparisons tests were performed to evaluate differences (right). **b**, Correlation
 between PD-1^{high}CXCR5⁻ Tph cells (percentage of CD3⁺CD4⁺CD45RA⁻ memory T cells) and
 - 17 -

plasmablasts (percentage of CD19⁺ B cells) in COVID-19 patients (both stable and 485 progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). 486 Correlation statistics is two-tailed Spearman's rank correlation test. c, Principal component 487 analysis (PCA) of RNA-seq transcriptomes (n=3, COVID-19 patients). Based on the 488 expression levels of PD-1 and CXCR5, six subsets (i)-(vi) were evaluated d, Heatmap of 489 Tfh-related genes¹⁹ among six subsets of memory CD4+ T cells. **e**, Clustered heatmap of 100 490 genes that were differentially expressed (left column) in PD-1^{high}CXCR5⁻ Tph cells compared 491 with cTfh cells (PD-1^{high}CXCR5+ Tph cells) (|Log2FC| >1, FDR <0.05). The right column shows 492 the log2 fold change for PD-1^{high}CXCR5⁻ Tph cells compared to cTfh cells. **f**, Representative 493 flow data of CCR5 and CCR2 expression on PD-1^{high}CXCR5⁻ Tph cells compared with PD-494 1^{high}CXCR5⁺ Tph cells. 495

496

497 **Figure 3**

498 The functions of PD-1^{high}CXCR5⁻ Tph cells

PD-1^{high}CXCR5⁻ Tph cells promote B cell differentiation and produce IFN_Y much higher than 499 500 cTfh cells, which affects the expression levels of tissue-homing receptors on plasmablasts. ab, Each T cell subset and autologous CD20+CD27+ B cells were sorted and co-cultured with 501 502 SEB and LPS for 7 days (n=5, COVID-19 patients). Representative flow data of CD27^{high}CD138+ plasma cells after co-culture (a). IgG concentrations in supernatants of co-503 504 cultures were evaluated by One-way ANOVA with Dunn's multiple comparisons tests (b). c. Sorted T cells (n=4, COVID-19 patients) were stimulated with anti-CD3/28 (each 1 µg/ml) for 505 48 hrs, then cytokine production levels were measured (IFN_γ, IL-17A, IL-10). **d-f**, Sorted 506 CD20⁺CD27⁺ memory B cells (n=5, healthy donors) were cultured with CD40L (0.05 ng/ml), 507 IL-21 (20ng/ml), and IL-10 (10 ng/ml) or different concentration of IFN γ (0, 3, 10, 30 ng/ml) for 508 7 days (n=5, healthy controls). Representative histogram of flow data for CXCR3 expression 509 on plasma cells (d, left), CXCR3 gMFI was evaluated by One-way ANOVA with Tukey's 510 multiple comparisons tests (d, right). After 7 days in culture, CD19⁺CD27⁺CD138⁺ plasma cells 511 were sorted and gene expression measured relative to B2M by gPCR (e, f). The expression 512 513 levels were evaluated by One-way ANOVA with Tukey's multiple comparisons tests (c-f).

- 514
- 515
- 516

517 Figure 4

Activated PD-1^{high}CXCR5⁻ Tph cells are significantly increased in stable COVID-19 518

patients and positively correlated with CXCR3+ plasmablasts. 519

a, Venn diagrams showing the overlapped genes among those significantly upregulated 520 (Log2FC>1, FDR<0.05) (left) and downregulated (Log2FC<-1, FDR<0.05) (right) in PD-521 1^{high}CXCR5⁻ Tph cells compared with five subsets as indicated. **b**, Heatmap of PD-522 1^{high}CXCR5⁻ Tph cells-related genes (selected in **a**) among each T cell subset from RNA-seq 523 data. **c**, Heatmap of PD-1^{high}CXCR5⁻ Tph cells-related genes (selected in **a**) among each T 524 cell cluster of our scRNA-seq dataset reported⁵. **d**, Representative flow data for each T cell 525 subset among HLA-DR⁺CD38⁺CD45RA⁻CD4⁺ T cells (left), and their proportions were 526 evaluated by One-way ANOVA with Dunn's multiple comparisons tests (right). COVID-19 527 528 samples which have more than 5% of HLA-DR⁺CD38⁺ T cells among memory CD4+ T cells were evaluated (n=11). e, Representative flow data of HLA-DR⁺CD38⁺ activated cells in PD-529 1^{high}CXCR5⁻ Tph cells between stable and progressive COVID-19 patients (up). The 530 proportions of activated PD-1^{high}CXCR5⁻ Tph cells were evaluated (stable; n= 56, progressive; 531 532 n= 36) by two-tailed unpaired Student's t-test (down). g, Correlation between activated PD-1^{high}CXCR5⁻ Tph cells (percentage of CD3⁺CD4⁺CD45RA⁻ memory T cells) and CXCR3⁺ 533 534 plasmablasts (percentage of CD19⁺CD27⁺CD38⁺ plasmablasts) (both stable and progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation 535 536 statistics is two-tailed Spearman's rank correlation test.

537 Supplemental Figure Legends

538 Supplemental Figure 1

539 The characteristics of each B cell subset in scRNA-seq dataset.

a, Bar plot showing cell compositions of each cluster by samples. **b**, Box plot showing other 540 canonical markers. The median is marked by a horizontal line with whiskers extending to the 541 farthest point within a maximum of 1.5 x interguartile range. Each dot corresponds to each 542 sample. c, Simpson's diversity of B cell clones within each plasmablast cluster. Each dot 543 corresponds to a patient (combined early and late samples), and dots from the same patient 544 are connected with dotted lines. **d**, The proportion of unmutated clones within each cell type 545 cluster based on immunoglobulin isotypes. Each dot corresponds to a patient, and a Wilcoxon 546 test p value is reported above plasmablast clusters. e, Comparison of cell counts (percentage 547 548 of total B cells) among each group (one-way ANOVA with Dunnet's multiple comparisons test). Each dot corresponds to each sample, and One-way ANOVA with Dunn's multiple 549 550 comparisons test was performed. f, Heatmap of gene expressions related to B cell functions³¹ in each cluster. All the samples are evaluated. 551

552

553 Supplemental Figure 2

554 **The characteristics of each T cell subset.**

a, Gating strategy to identify each T cell subset in PBMCs. Six subsets were detected based 555 on the expression levels of PD-1 and CXCR5, and activated T cells were defined as HLA-556 DR⁺CD38⁺ T cells. **b**, The proportion of each T cell subset among healthcare workers (HC) 557 (n=55), stable COVID-19 patients (Stable) (n=56), and progressive patients (Progressive) 558 (n=36). One-way ANOVA with Dunn's multiple comparisons tests were evaluated. n.s. = no 559 significance among each group. c, Correlation between each T cell subset (percentage of 560 CD3⁺CD4⁺CD45RA⁻ memory T cells) and plasmablasts (percentage of CD19⁺ B cells) in 561 COVID-19 patients (both stable and progressive, n=51). Linear regression is shown with 95% 562 confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation 563 test. 564

565

566 Supplemental Figure 3

567 The characteristics of PD-1^{high}CXCR5⁻ Tph cells.

a-b, Correlation between the proportion of PD-1^{high}CXCR5⁻ Tph cells (percentage of 568 CD3+CD4⁺CD45RA⁻ memory T cells) and each clinical background in COVID-19 patients 569 (both stable and progressive, n=92) (a, age; b, BMI). Linear regression is shown with 95% 570 confidence interval (gray area). Correlation statistics by two-tailed Spearman's rank 571 correlation test (**a**, **b**). **c**, The proportion of PD-1^{high}CXCR5⁻ Tph cells between male (n=45) 572 and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired Student's t-test. 573 d, Representative flow data of CX3CR1 expression on PD-1^{high}CXCR5⁻ Tph cells compared 574 with PD-1^{high}CXCR5⁺ Tfh cells. e, Heatmap of T cell lineage genes among six subsets of 575 memory CD4⁺ T cells. 576

577

578 Supplemental Figure 4

579 **PD-1**^{high}**CXCR5**⁻ **Tph cells from another COVID-19 dataset.**

Deposited flow cytometry data from another study⁶ were analyzed for validation of the 580 characteristics of PD-1^{high}CXCR5⁻ Tph cells in the acute phase of COVID-19 patients. **a**, 581 Representative flow data of PD-1^{high}CXCR5⁻ Tph cells in healthy donors (HC), recovered 582 583 donors from COVID-19 (RD), and hospitalized COVID-19 patients (COVID). b, The proportion of PD-1^{high}CXCR5⁻ Tph cells among HC (n=56), RD (n=36), and COVID (n=109; all at baseline 584 585 samples) groups. One-way ANOVA with Dunn's multiple comparisons tests were performed to evaluate differences. c, Correlation between PD-1^{high}CXCR5⁻ Tph cells (percentage of 586 CD3⁺CD4⁺CD45RA⁻ non-naive T cells) and plasmablasts (percentage of CD19⁺ B cells) in 587 COVID-19 patients (n=109). Linear regression is shown with 95% confidence interval (gray 588 area). Correlation statistics is two-tailed Spearman's rank correlation test. 589

590

591 Supplemental Figure 5

592 The characteristics of HLA-DR+CD38+ activated PD-1^{high}CXCR5⁻ Tph cells.

a, Representative flow data of CXCR6 and LAG3 on each T cell subset. **b**, LAG3 (left) and CXCR6 (right) gMFI of each T cell subset were evaluated (n=4, COVID-19 patients). **c-d**, Correlation between the proportion of activated HLA-DR⁺CD38⁺PD-1^{high}CXCR5⁻ Tph cells (percentage of PD-1^{high}CXCR5⁻ Tph cells) and each clinical background in COVID-19 patients (both stable and progressive, n=92)(**c**, age; **d**, BMI). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation test (**c**, **d**). **e**, The proportion of activated HLA-DR⁺CD38⁺PD-1^{high}CXCR5⁻ Tph cells between

male (n=45) and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired Student's t-test. **f-g**, Longitudinal frequencies of PD-1^{high}CXCR5⁻ Tph cells (**f**) and activated PD-1^{high}CXCR5⁻ Tph cells (**g**) after hospitalization. Only the samples which could follow blood collection (hospitalization, week1 of day1-7, week2 of day8-14) were analyzed (Stable n=23, Progressive n=16). At each time point, Two-tailed unpaired Student's t-test were performed (*p<0.05).

606

607 Supplemental Figure 6

608 Schematic model of T-B interactions in a) healthy donors, b) stable COVID-19

609 patients, and c) progressive COVID-19 patients in acute phase.

Under healthy conditions, we can detect few plasmablasts and PD-1^{high}CXCR5⁻ Tph cells. In 610 611 the acute phase, PD-1^{high}CXCR5⁻ Tph cells increased in COVID-19 patients and are related 612 to the promotion of plasmablasts. Among patients with COVID-19, stable groups can increase 613 activated PD-1^{high}CXCR5⁻ Tph cells quickly, which can produce IFN_γ more than PD-1^{high}CXCR5⁺ Tfh cells, and promote inflammatory-tissue homing plasmablasts at the proper 614 615 timing. Progressive COVID-19 patients can also increase activated PD-1^{high}CXCR5⁻Tph cells but delayed, which lead to insufficient promotion of plasmablasts at proper timing and worse 616 617 clinical outcome.

618

619 Acknowledgments

- We would like to thank all the hospital staff who helped care for the patients and obtain 620 samples. We are also grateful to all the members of YALE IMPACT research team who 621 obtained data. We also thank Yale Environmental Health and Safety (EHS) office, 622 particularly Dr. Maren Schniederberend, for providing the safety guidance for working with 623 COVID19 samples; Dr. Kevin O'Connor and C. Philip for feedback and discussions; Drs. L. 624 Devine and C. Wang for assistance with FACS based cell sorting; Drs. G. Wang and C. 625 Castaldi at Yale Center for Genome Analysis for support with 10x Genomics library 626 preparation and sequencing. We also thank Mei Zhang for preparation of bulk RNA-seq 627 libraries and sequencing. H.A. thanks Dailchi Sankyo Foundation of Life Science and 628 Uehara Memorial Foundation for his scholarship. D.A.H, A.I., S.H.K., R.R.M., and A.C.S. 629 630 thank the HIPC Consortium for valuable input.
- 631

632 Funding statement

- 633 This study was supported by grants to D.A.H. from the National Institutes of Health (NIH)
- 634 (U19 Al089992, R25 NS079193, P01 Al073748, U24 Al11867, R01 Al22220, UM
- 635 1HG009390, P01 Al039671, P50 CA121974, and R01 CA227473), the National Multiple
- 636 Sclerosis Society (NMSS) (CA 1061- A-18 and RG-1802-30153), the Nancy Taylor
- 637 Foundation for Chronic Diseases, and Erase MS (D.A.H); N.K. from NIH (R01HL127349,
- 638 R01HL141852 and U01HL145567); K.B.H. and S.H.K. from NIH (R01AI104739); A.I. from
- 639 NIH (R01AI157488 and R01NS111242) ; A.C.S. from NIH (K24AG042489). RNA sequencing
- 640 service was conducted at Yale Center for Genome Analysis and Yale Stem Cell Center
- 641 Genomics Core facility, the latter supported by the Connecticut Regenerative Medicine
- 642 Research Fund and the Li Ka Shing Foundation.
- 643

644 **Competing interest statement**

- D.A.H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and
- 646 Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb,
- 647 Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis
- 648 Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Further
- 649 information regarding funding is available on:
- 650 <u>https://openpaymentsdata.cms.gov/physician/166753/general-payments</u>

- N.K. reports personal fees from Boehringer Ingelheim, Third Rock, Pliant, Samumed,
- NuMedii, Indalo, Theravance, LifeMax, Three Lake Partners, RohBar in the last 36 months,
- and Equity in Pliant. N.K. is also a recipient of a grant from Veracyte and nonfinancial
- 654 support from Miragen. In addition, N.K. has patents on New Therapies in Pulmonary Fibrosis
- and ARDS (unlicensed) and Peripheral Blood Gene Expression as biomarkers in IPF
- 656 (licensed to biotech) all outside the submitted work. S.H.K. receives consulting fees from
- 657 Northrop Grumman.
- 658

659 Author Contributions

- 660 Overall study design; H.A., D.A.H., T.S.S.
- Biospecimen collection/processing; H.A., M.S., M.C., W.E.R., P.W., K.R., O.C., A.U., B.E.,
- 662 R.R.M., A.I., A.C.S, T.S.S.
- 663 Data analysis; H.A., W.R., K.B.H., I.C., S.C., S.H.K., C.D.C., N.K.,
- 664 Original draft writing; H.A.
- 665 Supervising the study; S.H.K., C.D.C., N.K., A.C.S, D.A.H., T.S.S.
- Reviewing and editing the manuscript; All authors participated in editing the manuscript.
- 667
- 668
- 669

670 **References**

Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons from the 1. 671 672 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J. 673 Am. Med. Assoc. 323, 1239-1242 (2020). 674 675 2. Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 382, 727-733 (2020). 676 Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 677 3. disease outcomes. Nature 588, 315-320 (2020). 678 4. Giamarellos-Bourboulis, E. J. et al. Complex Immune Dysregulation in COVID-19 679 Patients with Severe Respiratory Failure. Cell Host Microbe 27, 992-1000.e3 (2020). 680 Unterman, A. et al. Single-Cell Omics Reveals Dyssynchrony of the Innate and 681 5. 682 Adaptive Immune System in Progressive COVID-19. medRxiv 2020.07.16.20153437 683 (2020). doi:10.1101/2020.07.16.20153437 6. Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals patient 684 685 heterogeneity and distinct immunotypes with implications for therapeutic interventions. Science 369, eabc8511 (2020). 686 7. Kratzer, B. et al. Immunological imprint of COVID-19 on human peripheral blood 687 688 leukocyte populations. Allergy (2020). doi:10.1111/all.14647 8. Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with 689 COVID-19. Nat. Med. 26, 842-844 (2020). 690 McElroy, A. K. et al. Human Ebola virus infection results in substantial immune 691 9. activation. Proc. Natl. Acad. Sci. 112, 4719-4724 (2015). 692 Wrammert, J. et al. Rapid and Massive Virus-Specific Plasmablast Responses during 693 10. Acute Dengue Virus Infection in Humans. J. Virol. 86, 2911–2918 (2012). 694 695 11. Alon, R. et al. Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. Nat. Rev. Immunol. 21, 49-64 (2021). 696 12. Kunkel, E. J. & Butcher, E. C. Plasma-cell homing. Nat. Rev. Immunol. 3, 822-829 697 698 (2003). 699 13. Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of 700 antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160-171 (2015). 14. Ueno, H. T follicular helper cells in human autoimmunity. Curr. Opin. Immunol. 43, 701 24-31 (2016). 702 703 15. Crotty, S. Review T Follicular Helper Cell Biology : A Decade of Discovery and 704 Diseases. Immunity 50, 1132-1148 (2019). Morita, R. et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular 705 16.

706		cells and contain specific subsets that differentially support antibody secretion.
707		Immunity 34 , 108–121 (2011).
708	17.	Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in
709		recovered patients with COVID-19. <i>Nat. Med.</i> 26 , 1428–1434 (2020).
710	18.	Kaneko, N. <i>et al.</i> Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal
711		Centers in COVID-19. <i>Cell</i> 183 , 143-157.e13 (2020).
712	19.	Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells
713		in rheumatoid arthritis. <i>Nature</i> 542 , 110–114 (2017).
714	20.	Yoshitomi, H. & Ueno, H. Shared and distinct roles of T peripheral helper and T
715		follicular helper cells in human diseases. Cell. Mol. Immunol. (2020).
716		doi:10.1038/s41423-020-00529-z
717	21.	Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe
718		COVID-19. Nature 584, 463–469 (2020).
719	22.	Zhang, JY. et al. Single-cell landscape of immunological responses in patients with
720		COVID-19. Nat. Immunol. 21, 1107–1118 (2020).
721	23.	Won, WJ. & Kearney, J. F. CD9 Is a Unique Marker for Marginal Zone B Cells, B1
722		Cells, and Plasma Cells in Mice. <i>J. Immunol.</i> 168 , 5605 LP – 5611 (2002).
723	24.	Yoon, SO. et al. CD9 is a novel marker for plasma cell precursors in human germinal
724		centers. Biochem. Biophys. Res. Commun. 431, 41–46 (2013).
725	25.	Kim, C. C., Baccarella, A. M., Bayat, A., Pepper, M. & Fontana, M. F. FCRL5+
726		Memory B Cells Exhibit Robust Recall Responses. Cell Rep. 27, 1446-1460.e4
727		(2019).
728	26.	Pérez-Mazliah, D., Ndungu, F. M., Aye, R. & Langhorne, J. B-cell memory in malaria:
729		Myths and realities. Immunol. Rev. 293, 57–69 (2020).
730	27.	Jenks, S. A. et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor
731		7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity
732		49 , 725-739.e6 (2018).
733	28.	Riedel, R. et al. Discrete populations of isotype-switched memory B lymphocytes are
734		maintained in murine spleen and bone marrow. Nat. Commun. 11, 2570 (2020).
735	29.	Sanz, I. et al. Challenges and Opportunities for Consistent Classification of Human B
736		Cell and Plasma Cell Populations. Front. Immunol. 10, 2458 (2019).
737	30.	Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. EH. & Sanz, I. Extrafollicular
738		responses in humans and SLE. Immunol. Rev. 288, 136–148 (2019).
739	31.	Glass, D. R. et al. An Integrated Multi-omic Single-Cell Atlas of Human B Cell Identity.
740		Immunity 53 , 217-232.e5 (2020).
741	32.	Pattanapanyasat, K. et al. B cell subset alteration and the expression of tissue homing

742 molecules in dengue infected patients. J. Biomed. Sci. 25, 64 (2018). 33. Muehlinghaus, G. et al. Regulation of CXCR3 and CXCR4 expression during terminal 743 differentiation of memory B cells into plasma cells. Blood 105, 3965-3971 (2005). 744 Bocharnikov, A. V et al. PD-1hiCXCR5– T peripheral helper cells promote B cell 745 34. 746 responses in lupus via MAF and IL-21. JCI Insight 4, e130062 (2019). Conigliaro, P. et al. The type I IFN system in rheumatoid arthritis. Autoimmunity 43, 747 35. 220-225 (2010). 748 36. Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases. Nat. 749 750 Rev. Rheumatol. 14, 214–228 (2018). 751 37. Schmitt, N. *et al.* The cytokine TGF- β 2 co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFHcells. Nat. Immunol. 15, 856–865 (2014). 752 Sumida, T. S. et al. Type I Interferon Transcriptional Network Regulates Expression of 753 38. Coinhibitory Receptors in Human T cells. *bioRxiv: the preprint server for biology* 754 (2020). doi:10.1101/2020.10.30.362947 755 756 39. Woodruff, M. C. et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 21, 1506-1516 (2020). 757 40. Ramaswamy, A. et al. Post-infectious inflammatory disease in MIS-C features 758 elevated cytotoxicity signatures and autoreactivity that correlates with severity. 759 medRxiv: the preprint server for health sciences (2020). 760 761 doi:10.1101/2020.12.01.20241364 762 41. Lam, J. H. & Baumgarth, N. The Multifaceted B Cell Response to Influenza Virus. J. Immunol. 202, 351-359 (2019). 763 42. Elsner, R. A. & Shlomchik, M. J. Germinal Center and Extrafollicular B Cell 764 Responses in Vaccination, Immunity, and Autoimmunity. Immunity 53, 1136–1150 765 766 (2020). 43. Cunningham, A. F. et al. Salmonella induces a switched antibody response without 767 germinal centers that impedes the extracellular spread of infection. J. Immunol. 178, 768 6200-6207 (2007). 769 Lucas, C. et al. Kinetics of antibody responses dictate COVID-19 outcome. medRxiv 770 44. 2020.12.18.20248331 (2020). doi:10.1101/2020.12.18.20248331 771 Chen, Y. et al. A comprehensive, longitudinal analysis of humoral responses specific 772 45. to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 773 patients. PLOS Pathog. 16, e1008796 (2020). 774 Kofler, D. M., Severson, C. A., Mousissian, N., De Jager, P. L. & Hafler, D. A. The 46. 775 776 CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation. J. Immunol. 187, 3286-3291 (2011). 777

778	47.	Karakas Celik, S., Cakmak Genc, G. & Dursun, A. A bioinformatic approach to
779		investigating cytokine genes and their receptor variants in relation to COVID-19
780		progression. Int. J. Immunogenet. (2020). doi:10.1111/iji.12522
781	48.	Remy, M. M. et al. Effective chemical virus inactivation of patient serum compatible
782		with accurate serodiagnosis of infections. Clin. Microbiol. Infect. Off. Publ. Eur.
783		Soc. Clin. Microbiol. Infect. Dis. 25, 907.e7-907.e12 (2019).
784	49.	Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
785		transcriptomic data across different conditions, technologies, and species. Nat.
786		Biotechnol. 36 , 411–420 (2018).
787	50.	Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-
788		1902.e21 (2019).
789	51.	Giudicelli, V., Chaume, D. & Lefranc, MP. IMGT/GENE-DB: a comprehensive
790		database for human and mouse immunoglobulin and T cell receptor genes. Nucleic
791		Acids Res. 33 , D256-61 (2005).
792	52.	Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin variable
793		domain sequence analysis tool. <i>Nucleic Acids Res.</i> 41, W34-40 (2013).
794	53.	Gupta, N. T. et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin
795		repertoire sequencing data. <i>Bioinformatics</i> 31 , 3356–3358 (2015).
796	54.	Yaari, G. et al. Models of somatic hypermutation targeting and substitution based on
797		synonymous mutations from high-throughput immunoglobulin sequencing data.
798		Front. Immunol. 4 , 358 (2013).
799	55.	Nielsen, S. C. A. et al. Human B Cell Clonal Expansion and Convergent Antibody
800		Responses to SARS-CoV-2. Cell Host Microbe 28, 516-525.e5 (2020).
801	56.	Cantu, V. A., Sadural, J. & Edwards, R. PRINSEQ++, a multi-threaded tool for fast
802		and efficient quality control and preprocessing of sequencing datasets. PeerJ Prepr.
803		43–45 (2019). doi:10.7287/peerj.preprints.27553
804	57.	Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21
805		(2013).
806	58.	Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data
807		with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
808	59.	Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
809		dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
810		



Figure 1 The divergent immunological features of B cells in stable and progressive COVID-19 patients

Plasmablasts of patients with stable COVID-19 express inflammatory tissue-homing receptors. **a**, Representative flow data of CD19⁺CD27⁺CD38⁺ plasmablasts (left). The proportion of plasmablasts between healthcare workers (HCs) (n=15) and both stable and progressive COVID-19 patients (COVID) (n=51) were evaluated by two-tailed unpaired Student' s t-test were evaluated (right). **b**, UMAP representation of sub-clustered B cells from HCs (n = 13) and COVID-19 samples (n = 18 from 10 patients). Eight subclusters were identified. **c**, Canonical cell markers for cluster delineation. Data are colored according to expression levels. **d**, Fractional abundance of IGHA (dark green), IGHD (orange), IGHG (pink), and IGHM (light green) cells in each cluster. PBs denote plasmablasts. **e**, Frequency of somatic hypermutation (SHM) in each cluster. Each dot denotes a patient (combined early and late samples, n=10). A Wilcoxon test was evaluated, and p value is reported above plasmablast clusters. PBs denote plasmablasts. Average expression per subject for each gene is shown. **g**, Representative flow data of CXCR3 expression on CD19⁺CD27⁺CD38⁺ plasmablasts in COVID-19 patients (left). The proportions of CXCR3⁺ plasmablasts between stable (n= 31) and progressive (n=20) COVID-19 patients were evaluated by two-tailed unpaired Student' s t-test (right).



Figure 2 The characteristics of PD-1^{high}CXCR5⁻ Tph cells

PD-1^{high}CXCR5⁻ Tph cells have characteristic gene expressions and are increased in COVID-19 patients. **a**, Representative flow data of PD-1^{high}CXCR5⁻ Tph cells in each group (left), the proportion of these T cells among healthcare workers (HC) (n=55), stable COVID-19 patients (Stable) (n=56), and progressive patients (Progressive) (n=36). One-way ANOVA with Dunn' s multiple comparisons tests were performed to evaluate differences (right). **b**, Correlation between PD-1^{high}CXCR5⁻ Tph cells (percentage of CD3⁺CD4⁺CD45RA⁻ memory T cells) and plasmablasts (percentage of CD19⁺ B cells) in COVID-19 patients (both stable and progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman' s rank correlation test. **c**, Principal component analysis (PCA) of RNA-seq transcriptomes (n=3, COVID-19 patients). Based on the expression levels of PD-1 and CXCR5, six subsets (i)-(vi) were evaluated **d**, Heatmap of Tfh-related genes19 among six subsets of memory CD4+ T cells. **e**, Clustered heatmap of 100 genes that were differentially expressed (left column) in PD-1^{high}CXCR5⁻ Tph cells compared to cTfh cells (PD-1^{high}CXCR5⁺ Tph cells) (|Log2FC| >1, FDR <0.05). The right column shows the log2 fold change for PD-1^{high}CXCR5⁻ Tph cells compared to cTfh cells. **f**, Representative flow data of CCR5 and CCR2 expression on PD-1^{high}CXCR5⁻ Tph cells compared with PD-1^{high}CXCR5⁺ Tfh cells.



Figure 3 The functions of PD-1^{high}CXCR5⁻ Tph cells

PD-1^{high}CXCR5⁻ Tph cells promote B cell differentiation and produce IFN_Y much higher than cTfh cells, which affects the expression levels of tissue-homing receptors on plasmablasts. **a-b**, Each T cell subset and autologous CD20⁺CD27⁺ B cells were sorted and co-cultured with SEB and LPS for 7 days (n=5, COVID-19 patients). Representative flow data of CD27^{high}CD138⁺ plasma cells after co-culture (**a**). IgG concentrations in supernatants of co-cultures were evaluated by One-way ANOVA with Dunn's multiple comparisons tests (**b**). **c**, Sorted T cells (n=4, COVID-19 patients) were stimulated with anti-CD3/28 (each 1 μ g/ml) for 48 hrs, then cytokine production levels were measured (IFN_Y, IL-17A, IL-10). **d-f**, Sorted CD20⁺CD27⁺ memory B cells (n=5, healthy donors) were cultured with CD40L (0.05 ng/ml), IL-21 (20ng/ml), and IL-10 (10 ng/ml) or different concentration of IFN_Y (0, 3, 10, 30 ng/ml) for 7 days (n=5, healthy controls). Representative histogram of flow data for CXCR3 expression on plasma cells (**d**, left), CXCR3 gMFI was evaluated by One-way ANOVA with Tukey's multiple comparisons tests (**d**, right). After 7 days in culture, CD19⁺CD27 ⁺CD138⁺ plasma cells were sorted and gene expression measured relative to B2M by qPCR (**e**, **f**). The expression levels were evaluated by One-way ANOVA with Tukey's multiple comparisons tests (**c-f**).



Figure 4 Activated PD-1^{high}CXCR5⁻ Tph cells are significantly increased in stable COVID-19 patients and positively correlated with CXCR3⁺ plasmablasts

a, Venn diagrams showing the overlapped genes among those significantly upregulated (Log2FC>1, FDR<0.05) (left) and downregulated (Log2FC<-1, FDR<0.05) (right) in PD-1^{high}CXCR5⁻ Tph cells compared with five subsets as indicated. **b**, Heatmap of PD-1^{high}CXCR5⁻ Tph cells-related genes (selected in a) among each T cell subset from RNA-seq data. **c**, Heatmap of PD-1^{high}CXCR5⁻ Tph cells-related genes (selected in a) among each T cell subset from RNA-seq data. **c**, Heatmap of PD-1^{high}CXCR5⁻ Tph cells-related genes (selected in a) among each T cell cluster of our scRNA-seq dataset reported⁵. **d**, Representative flow data for each T cell subset among HLA-DR*CD38*CD45RA-CD4* T cells (left), and their proportions were evaluated by One-way ANOVA with Dunn' s multiple comparisons tests (right). COVID-19 samples which have more than 5% of HLA-DR*CD38* T cells among memory CD4* T cells were evaluated (n=11). **e**, Representative flow data of HLA-DR*CD38* activated cells in PD-1^{high}CXCR5⁻ Tph cells between stable and progressive COVID-19 patients (up). The proportions of activated PD-1^{high}CXCR5⁻ Tph cells were evaluated (stable; n= 56, progressive; n= 36) by two-tailed unpaired Student' s t-test (down). **f**, Correlation between activated PD-1^{high}CXCR5⁻ Tph cells (percentage of CD3*CD4*CD4*CD45RA⁻ memory T cells) and CXCR3⁺ plasmablasts (percentage of CD19*CD27*CD38* plasmablasts) (both stable and progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman' s rank correlation test.



Supplemental Figure 1 The characteristics of each B cell subset in scRNA-seq dataset

a, Bar plot showing cell compositions of each cluster by samples. **b**, Box plot showing other canonical markers. The median is marked by a horizontal line with whiskers extending to the farthest point within a maximum of 1.5 x interquartile range. Each dot corresponds to each sample. **c**, Simpson's diversity of B cell clones within each plasmablast cluster. Each dot corresponds to a patient (combined early and late samples), and dots from the same patient are connected with dotted lines. **d**, The proportion of unmutated clones within each cell type cluster based on immunoglobulin isotypes. Each dot corresponds to a patient, and a Wilcoxon test p value is reported above plasmablast clusters. **e**, Comparison of cell counts (percentage of total B cells) among each group (one-way ANOVA with Dunnet's multiple comparisons test). Each dot corresponds to each sample, and One-way ANOVA with Dunn's multiple comparisons test was performed. **f**, Heatmap of gene expressions related to B cell functions³¹ in each cluster. All the samples are evaluated.



Supplemental Figure 2 The characteristics of each T cell subset

a, Gating strategy to identify each T cell subset in PBMCs. Six subsets were detected based on the expression levels of PD-1 and CXCR5, and activated T cells were defined as HLA-DR⁺CD38⁺ T cells. **b**, The proportion of each T cell subset among healthcare workers (HC) (n=55), stable COVID-19 patients (Stable) (n=56), and progressive patients (Progressive) (n=36). One-way ANOVA with Dunn' s multiple comparisons tests were evaluated. n.s. = no significance among each group. **c**, Correlation between each T cell subset (percentage of CD3⁺CD4⁺CD45RA⁻ memory T cells) and plasmablasts (percentage of CD19⁺ B cells) in COVID-19 patients (both stable and progressive, n=51). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman' s rank correlation test.



Supplemental Figure 3 The characteristics of PD-1^{high}CXCR5⁻ Tph cells.

a-b, Correlation between the proportion of PD-1^{high}CXCR5⁻ Tph cells (percentage of CD3⁺CD4⁺CD45RA⁻ memory T cells) and each clinical background in COVID-19 patients (both stable and progressive, n=92) (**a**, age; **b**, BMI). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics by two-tailed Spearman' s rank correlation test (**a**, **b**). **c**, The proportion of PD-1^{high}CXCR5⁻ Tph cells between male (n=45) and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired Student' s t-test. **d**, Representative flow data of CX3CR1 expression on PD-1^{high}CXCR5⁻ Tph cells compared with PD-1^{high}CXCR5⁺ Tfh cells. **e**, Heatmap of T cell lineage genes among six subsets of memory CD4⁺ T cells.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.13.21253527; this version posted March 17, 2021. The copyright holder for this Supplement and the copyright holder for this preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license . The Human Pancreas Analysis Program (HPAPRRID:SCR_016202) Database and Cytobank (Science 2020;369:eabc8511)



Supplemental Figure 4 PD-1^{high}CXCR5⁻ Tph cells from another COVID-19 dataset

Deposited flow cytometry data from another study⁶ were analyzed for validation of the characteristics of PD-1^{high}CXCR5⁻ Tph cells in the acute phase of COVID-19 patients. **a**, Representative flow data of PD-1^{high}CXCR5⁻ Tph cells in healthy donors (HC), recovered donors from COVID-19 (RD), and hospitalized COVID-19 patients (COVID). **b**, The proportion of PD-1^{high}CXCR5⁻ Tph cells among HC (n=56), RD (n=36), and COVID (n=109; all at baseline samples) groups. One-way ANOVA with Dunn's multiple comparisons tests were performed to evaluate differences. **c**, Correlation between PD-1^{high}CXCR5⁻ Tph cells (percentage of CD3⁺CD4⁺CD45RA⁻ non-naive T cells) and plasmablasts (percentage of CD19⁺ B cells) in COVID-19 patients (n=109). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman's rank correlation test.



Supplemental Figure 5 The characteristics of HLA-DR⁺CD38⁺ activated PD-1^{high}CXCR5⁻ Tph cells a, Representative flow data of CXCR6 and LAG3 on each T cell subset. b, LAG3 (left) and CXCR6 (right) gMFI of each T cell subset were evaluated (n=4, COVID-19 patients). c-d, Correlation between the proportion of activated HLA-DR⁺CD38⁺PD-1^{high}CXCR5⁻ Tph cells (percentage of PD-1^{high}CXCR5⁻ Tph cells) and each clinical background in COVID-19 patients (both stable and progressive, n=92)(c, age; d, BMI). Linear regression is shown with 95% confidence interval (gray area). Correlation statistics is two-tailed Spearman' s rank correlation test (c, d). e, The proportion of activated HLA-DR⁺CD38⁺PD-1^{high}CXCR5⁻ Tph cells between male (n=45) and female (n=47) COVID-19 patients were evaluated by two-tailed unpaired Student' s t-test. f-g, Longitudinal frequencies of PD-1^{high}CXCR5⁻ Tph cells (f) and activated PD-1^{high}CXCR5⁻ Tph cells (g) after hospitalization. Only the samples which could follow blood collection (hospitalization, week1 of day1-7, week2 of day8-14) were analyzed (Stable n=23, Progressive n=16). At each time point, Two-tailed unpaired Student' s t-test were performed (*p<0.05). medRxiv preprint doi: https://doi.org/10.1101/2021.03.13.21253527; this version posted March 17, 2021. The copyright holder for this Supplement who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Supplemental Figure 6 Schematic model of T-B interactions in a) healthy donors, b) stable COVID-19 patients, and c) progressive COVID-19 patients in acute phase

Under healthy conditions, we can detect few plasmablasts and PD-1^{high}CXCR5⁻ Tph cells. In the acute phase, PD-1^{high}CXCR5⁻ Tph cells increased in COVID-19 patients and are related to the promotion of plasmablasts. Among patients with COVID-19, stable groups can increase activated PD-1^{high}CXCR5⁻ Tph cells quickly, which can produce IFN_γ more than PD-1^{high}CXCR5⁺ Tfh cells, and promote inflammatory-tissue homing plasmablasts at the proper timing. Progressive COVID-19 patients can also increase activated PD-1^{high}CXCR5⁻Tph cells but delayed, which lead to insufficient promotion of plasmablasts at proper timing and worse clinical outcome.